ArticleThe American journal of pathology1995
Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease.
Article in The American journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 147 citations in OpenAlex.
- The CML/esRAGE ratio as a potential biomarker of early diastolic impairment in asymptomatic type 1 diabetic patients without overt heart disease.BMC cardiovascular disorders · 2026Article
- The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.Journal of clinical medicine · 2023Review
- Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?Nutrients · 2022Review
- Molecularly targeted nanoparticles: an emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease.Cellular & molecular biology letters · 2021Article
- Novel Receptor for Advanced Glycation End Products-Blocking Antibody to Treat Diabetic Peripheral Artery Disease.Journal of the American Heart Association · 2021Article
- AGE-RAGE Axis in the Pathophysiology of Chronic Lower Limb Ischemia and a Novel Strategy for Its Treatment.The International journal of angiology : official publication of the International College of Angiology, Inc · 2020Review
- Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus.Journal of atherosclerosis and thrombosis · 2018Review
- Article
- The Glyoxalase System and Methylglyoxal-Derived Carbonyl Stress in Sepsis: Glycotoxic Aspects of Sepsis Pathophysiology.International journal of molecular sciences · 2017Review
- The receptor for advanced glycation end products impairs collateral formation in both diabetic and non-diabetic mice.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- From Human Megakaryocytes to Platelets: Effects of Aspirin on High-Mobility Group Box 1/Receptor for Advanced Glycation End Products Axis.Frontiers in immunology · 2017Article
- Polymorphisms in three genes are associated with hemorrhagic stroke.Brain and behavior · 2015Article
- Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study.Cardiovascular diabetology · 2015Article
- Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.Diagnostics (Basel, Switzerland) · 2015Review
- Altered Expression of NF- κ B and SP1 after Exposure to Advanced Glycation End-Products and Effects of Neurotrophic Factors in AGEs Exposed Rat Retinas.Journal of diabetes research · 2015Article
- Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality.The International journal of angiology : official publication of the International College of Angiology, Inc · 2014Review
- Imaging RAGE expression in atherosclerotic plaques in hyperlipidemic pigs.EJNMMI research · 2014Article
- Imaging receptor for advanced glycation end product expression in mouse model of hind limb ischemia.EJNMMI research · 2013Article
- Association of the receptor for advanced glycation end products gene polymorphisms and circulating RAGE levels with diabetic retinopathy in the Chinese population.Journal of diabetes research · 2013Article
- Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity.Neurobiology of aging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least in part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.
Indexed as
Identifiers
7887450PMC1869189W90630212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.